StockStory Flags EPAM at $5.09 Billion, Warns on Covista and Myriad Genetics

1 articles · Updated · Yahoo Finance · Aug 18

StockStory singled out EPAM Systems as its small-cap stock to watch, while naming Covista and Myriad Genetics as likely underperformers.
Covista, valued at $4.50 billion, drew a negative view because its 16.6% five-year annual revenue growth lagged peers, its free-cash-flow margin is projected to fall 5.8 points next year, and return on capital was 9.3%.
Myriad Genetics, with a $291.7 million market cap, was flagged for flat sales over the past two years, a 7.4% annual drop in EPS despite revenue growth, and unprofitable operations that could force more dilutive share issuance.
The screening reflects StockStory's pitch that thinner Wall Street coverage in small caps can create upside opportunities but also higher downside risk than larger, more established companies.